Bernstein lowered the firm’s price target on Guardant Health (GH) to $35 from $40 and keeps an Outperform rating on the shares. With the large, diversified tools companies taking a hit this earnings season, the firm sees the diagnostics names as the safe place to be in the sector. Broadly, reimbursement tailwinds from the biomarker bills continue to help ASPs in the sector, with California’s bill now live and the introduction of a new bill from Hawaii. On the regulatory front, the FDA LDT regulation was enacted in Q2, though legal challenges have been mounting as expected, Bernstein adds.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Appoints Roberto Mignone to Board
- Guardant Health price target lowered to $50 from $60 at Leerink
- Guardant Health publishes SCRUM-Japan GOZILA study results
- Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI
- Guardant Health, Italy’s Policlinico Gemelli team on liquid biopsy testing